Left Atrial Appendage Closure Devices Market Analysis

Left Atrial Appendage Closure Devices Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is classified into endocardial LAA devices and epicardial LAA devices. The endocardial LAA devices segment generated the highest revenue of USD 1.6 billion in 2023.
 

• This significant market growth is due to increasing demand and surging awareness pertaining to the advantages delivered by endocardial LAA devices in treatment that minimizes the risk of LAA blood clots entering the main bloodstream. For instance, as per a published research article, the endocardial Watchman device commercialized by Boston Scientific Corporation has an implant procedure success rate of up to over 98%.
   
• Moreover, the endocardial LAA devices have proven to reduce the risk of thromboembolic events with acceptable procedure-related complication rates. Additionally, the implantation of endocardial LAA closure devices is observed as a feasible and safe option in the setting of a hybrid atrial fibrillation ablation.
   

Based on procedure, the left atrial appendage closure devices market is classified into percutaneous and surgical. The percutaneous segment accounted for the majority segmental share in 2023 and was valued at USD 1.7 billion in 2023.
 

• Percutaneous left atrial appendage (LAA) closure is a promising alternative to anticoagulation therapy for patients with atrial fibrillation at high risk for cerebrovascular events. Market players are emphasizing the designing of self-expanding devices to achieve successful percutaneous LAA closure.
   
• Percutaneous minimally invasive surgery that involves product insertion through a small incision, in most cases leaving minimal scarring only, has emerged as a preferred choice in the treatment of targeted disease conditions.
   
• Furthermore, in recent years, these procedures have rapidly grown worldwide as an appealing alternative for the prevention of thromboembolisms in patients at high risk for stroke, with a specific focus on patients ineligible for oral anticoagulants. For instance, the Watchman device, the FDA-approved percutaneous small device, is permanently placed in the opening of LAA to prevent harmful blood clots from exiting and entering the bloodstream.
   

Based on end use, the left atrial appendage closure devices market is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to reach USD 6 billion by the end of the forecast period.
 

• This majority market share is owing to the surging use of novel LAA closure devices in hospital settings offering enhanced operability, which is estimated to fuel patient preference for hospitals. Increasing admissions with target disorders due to a sedentary lifestyle and growing disease screening initiatives, coupled with the availability of highly skilled healthcare professionals, are some other attributes that are propelling the growth of the hospital segment positively.
   
• Moreover, the high prevalence of atrial fibrillation in developing countries with robust healthcare infrastructure is anticipated to positively impact segment growth. Surging cardiovascular and renal disease prevalence linked with atrial fibrillation is anticipated to further propel the diagnosis and treatment rates at hospitals.
   

North America left atrial appendage closure devices market generated USD 1.3 billion in revenue in 2023 and is projected to grow at a CAGR of 17.6% from 2024 to 2032.
 

• Key factors contributing to this market share include the presence of major industry players, increasing product demand, and rising atrial fibrillation cases. Companies like Boston Scientific Corporation and Abbott Laboratories are driving industry expansion through new product development and commercialization.
   
• The high prevalence of atrial fibrillation and increasing hospital admissions underscore the growing need for LAA closure devices. The Centers for Disease Control and Prevention (CDC) projects that approximately 12.1 million people in the U.S. will have atrial fibrillation by 2030. Consequently, LAAC device implantation is expected to increase, supporting market growth.
   

The U.S. left atrial appendage closure devices market reached USD 1.2 billion in revenue in 2023 and is expected to experience substantial growth from 2024 to 2032.
 

• Favorable reimbursement policies in the U.S. contribute to market growth. The Centers for Medicare and Medicaid Services (CMS) has expanded coverage for LAAC procedures, notably increasing reimbursement for Boston Scientific's WATCHMAN FLX device by 78% between 2015 and 2021. The weighted average reimbursement for LAAC procedures (DRG 273-274) also increased in 2022.
   
• This improved reimbursement landscape has encouraged more hospitals and healthcare providers to adopt LAAC devices, increasing treatment accessibility. The market has also benefited from extensive commercial payer coverage in the country.
   

Germany's left atrial appendage closure devices market is expected to grow significantly in the coming years.
 

• The German health system provides comprehensive reimbursement for LAAC procedures, encouraging hospitals to adopt these devices and increasing procedure volumes. This trend is likely to continue as other European countries improve their reimbursement frameworks.
   
• The expanding patient base and increasing acceptance of LAAC as a preferred stroke prevention strategy are driving market growth. Growing clinical evidence supporting LAAC's efficacy further reinforces this upward trajectory in the country.
   

Japan holds a leading position in the Asia Pacific left atrial appendage closure devices market.
 

• Increasing awareness among patients and healthcare professionals about LAAC procedure benefits is driving product demand. Educational initiatives and clinical training programs are enhancing understanding of LAAC benefits, leading to more informed patient decisions.
   
• The rising prevalence of atrial fibrillation (AF) is a primary factor driving market growth. According to the World Health Organization (WHO), the incidence of AF is expected to double by 2030, particularly affecting the aging population in Asian countries, including Japan.